MASI

+ Watchlist + Portfolio

Masimo Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Fundamentals are temporarily unavailable for MASI.

MASI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.04B	$1.28B	$1.40B	$1.53B
Cost of Revenue	$977.00M	$509.90M	$600.90M	$581.70M
Gross Profit	$1.06B	$765.60M	$794.30M	$945.20M
Research & Development	$191.40M	$130.50M	$182.20M	$126.40M
Selling, General & Admin	$657.40M	$451.30M	$548.60M	$506.00M
Operating Expenses	$848.80M	$581.80M	$730.80M	$632.40M
Operating Income	$210.00M	$183.80M	$63.50M	$312.80M
EBITDA	$355.20M	$199.00M	$111.50M	$344.60M
Pretax Income	$193.40M	$113.00M	$21.80M	$272.60M
Income Tax	$49.90M	$5.30M	$5.60M	$64.90M
Net Income	$143.50M	$81.50M	-$304.90M	-$151.50M
Diluted EPS	2.60	1.51	-5.72	-2.83
Diluted Shares	55.20M	54.10M	53.30M	54.20M

MASI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$202.90M	$163.00M	$123.60M	$152.30M
Receivables	$505.10M	$421.00M	$339.70M	$327.50M
Inventory	$501.00M	$545.00M	$294.80M	$380.30M
Current Assets	$1.31B	$1.23B	$1.23B	$926.00M
Total Assets	$3.21B	$3.04B	$2.63B	$1.70B
Current Liabilities	$630.00M	$563.80M	$617.70M	$371.60M
Long-Term Debt	$941.60M	$871.70M	$714.30M	$518.00M
Total Debt	$1.03B	$970.00M	$762.30M	$559.30M
Total Liabilities	$1.87B	$1.68B	$1.57B	$977.70M
Retained Earnings	$1.71B	$1.80B	$1.49B	$1.34B
Shareholders' Equity	$1.34B	$1.36B	$1.05B	$721.20M
Working Capital	$678.60M	$668.10M	$608.10M	$554.40M
Net Debt	$753.80M	$743.00M	$605.70M	$372.00M

MASI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$29.40M	$94.10M	$196.40M	$217.80M
Capital Expenditure	-$56.30M	-$61.80M	-$38.30M	-$24.70M
Free Cash Flow	-$26.90M	$32.30M	$158.10M	$193.10M
Depreciation & Amortisation	$136.10M	$38.90M	$48.50M	$38.80M
Stock-Based Compensation	$47.70M	$6.10M	$36.10M	$35.80M
Investing Cash Flow	-$1.06B	-$81.20M	-$51.20M	$275.10M
Financing Cash Flow	$520.40M	-$57.10M	-$125.60M	-$520.70M
Share Repurchases	-$401.50M	$0.00	$0.00	-$363.70M
Net Change in Cash	-$507.90M	-$44.20M	$19.60M	-$27.80M

MASI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$372.00M	$370.90M	$371.50M	$412.50M	$403.60M
Cost of Revenue	$138.00M	$137.60M	$140.90M	$165.20M	$152.80M
Gross Profit	$234.00M	$233.30M	$230.60M	$247.30M	$250.80M
Research & Development	$33.90M	$29.90M	$30.50M	$32.10M	$30.00M
Selling, General & Admin	$119.40M	$138.90M	$116.40M	$131.30M	$143.40M
Operating Expenses	$153.30M	$168.80M	$146.90M	$163.40M	$173.40M
Operating Income	$80.70M	$64.50M	$83.70M	$83.90M	$77.40M
EBITDA	$85.80M	$72.00M	$91.90M	$95.10M	$85.50M
Pretax Income	$68.40M	$55.40M	$74.90M	$74.00M	$71.30M
Income Tax	$21.20M	$10.50M	$21.20M	$12.10M	$15.00M
Net Income	-$170.70M	$51.30M	-$100.40M	$68.30M	$57.10M
Diluted EPS	-3.17	0.94	-1.86	—	1.09
Diluted Shares	54.80M	54.80M	54.40M	—	52.60M

MASI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$130.80M	$149.60M	$312.30M	$152.30M	$124.60M
Receivables	$346.60M	$352.50M	$355.90M	$327.50M	$288.90M
Inventory	$301.20M	$318.50M	$338.60M	$380.30M	$400.00M
Current Assets	$1.18B	$1.27B	$1.05B	$926.00M	$870.50M
Total Assets	$2.29B	$2.40B	$1.82B	$1.70B	$1.64B
Current Liabilities	$546.50M	$592.10M	$369.70M	$371.60M	$325.40M
Long-Term Debt	$636.00M	$598.70M	$559.10M	$518.00M	$445.70M
Total Debt	$681.50M	$642.20M	$586.20M	$559.30M	$485.90M
Total Liabilities	$1.35B	$1.36B	$1.01B	$977.70M	$853.80M
Retained Earnings	$1.32B	$1.37B	$1.27B	$1.34B	$1.40B
Shareholders' Equity	$946.40M	$1.04B	$810.00M	$721.20M	$788.90M
Working Capital	$637.50M	$677.70M	$678.60M	$554.40M	$545.10M
Net Debt	$520.20M	$464.10M	$246.80M	$372.00M	$327.40M

MASI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$31.10M	$69.40M	$56.80M	$60.50M	$45.30M
Capital Expenditure	-$4.10M	-$4.90M	-$7.10M	-$8.60M	-$5.30M
Free Cash Flow	$27.00M	$64.50M	$49.70M	$51.90M	$40.00M
Depreciation & Amortisation	$8.60M	$8.40M	$8.20M	$13.60M	$8.10M
Stock-Based Compensation	$9.10M	$8.50M	$9.30M	$8.90M	$8.90M
Investing Cash Flow	$10.70M	-$9.20M	$282.30M	-$8.70M	-$4.20M
Financing Cash Flow	-$47.80M	-$39.90M	-$218.40M	-$214.60M	-$70.20M
Share Repurchases	—	—	-$163.30M	-$186.70M	—
Net Change in Cash	-$6.00M	$20.30M	$118.70M	-$160.80M	-$29.10M

Market Snapshot

About

Masimo Corp. is a medical technology company that develops innovative noninvasive patient monitoring technologies. The company is best known for its Masimo SET pulse oximetry technology, which measures blood oxygen levels and pulse rate. Masimo products are used in hospitals, emergency medical services, and home care settings worldwide.